VivoSeq
Other

Untreated Advanced NSCLC

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Untreated Advanced NSCLC is an early-stage landscape with 0 programs across 2 companies. The most active players are Shanghai Henlius Biotech, Genfleet Therapeutics (Shanghai) Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

0 programs

PreclinicalG

Genfleet Therapeutics (Shanghai) Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Active, not recruiting1 · 33%
Completed1 · 33%

Clinical Trials

Trial Activity

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Recruiting·FFudan University·Phase 2·NCT07117890·34 enrolled
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
Active, not recruiting·Shanghai Henlius Biotech logoShanghai Henlius Biotech·Phase 2·NCT05787613·132 enrolled
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
Completed·GGenfleet Therapeutics (Shanghai) Inc.·Phase 1/2·NCT05756153·47 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)